Role of serum cytokine profile in ulcerative colitis assessment

Rodríguez-Perlvárez, Manuel Luis; García–Sánchez, Valle; Villar-Pastor, Carlos Manuel; González, Raál; Iglesias-Flores, Eva; Muntané, Jordi; Gómez-Camacho, Federico

doi:10.1002/ibd.22865

Cited by 51 publications

(44 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unexpectedly, we found an increased production of IL-8 in the CC genotype, which seems to be paradoxical to the results for IL-17, TNFα and IL-1β expression. A similar result was also reported in a study on ulcerative colitis in which the expression of IL-8 was inconsistent with that of IL-17 and IL-1β 36. Collectively, these results suggest that this SNP functionally affects the miR-146a expression level and also influences proinflammatory cytokine production.…”

Section: Discussionsupporting

confidence: 88%

MicroRNA-146aandEts-1gene polymorphisms in ocular Behçet's disease and Vogt–Koyanagi–Harada syndrome

et al. 2012

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 88%

MicroRNA-146aandEts-1gene polymorphisms in ocular Behçet's disease and Vogt–Koyanagi–Harada syndrome

et al. 2012

View full text Add to dashboard Cite

show abstract

“…In our patients, IL‐23 and IL‐17 A showed a tendency to increase during the apheresis doses. However, IL‐6 and IL‐8 levels tended to decrease, in line with previously published results that observed that the levels of these cytokines could be good indicators of disease activity . IL‐10 is an anti‐inflammatory cytokine.…”

Section: Discussionmentioning

confidence: 99%

“…However, IL-6 and IL-8 levels tended to decrease, in line with previously published results that observed that the levels of these cytokines could be good indicators of disease activity. 13 IL-10 is an anti-inflammatory cytokine. However, its beneficial effect in IBD is not yet clear, given IL-10 treatment in patients with IBD failed to induce clinical effects.…”

Section: Discussionmentioning

confidence: 99%

Adsorptive granulocyte/monocyte apheresis use in severe ulcerative colitis and determination of changes in plasma cytokines

Beltrán

Saéz-González

Moret

et al. 2017

J of Clinical Apheresis

View full text Add to dashboard Cite

Despite controversy regarding the use of granulocyte/monocyte adsorption (GMA) in inflammatory bowel disease, some studies have shown favorable outcomes when it is used in steroid-dependent patients with ulcerative colitis (UC). The mechanisms responsible for such outcomes are not well characterized, but changes in immune cell populations and cytokine levels have been suggested to play an important role. We report the cases of 3 patients with chronically active severe UC who underwent GMA due to an inadequate response to standard and rescue therapy, as well as changes to their plasma cytokine profile. All the patients presented severe UC that was only partially responsive to various immunosuppressive drugs, and they were, therefore, referred for colectomy; however, all 3 refused this option, which led to the compassionate use of GMA as a last therapeutic resort. Following GMA treatment, rapid normalization of the clinical, endoscopic and laboratory parameters was observed in all the patients. Despite having achieved a good response, most cytokines remained at high concentrations after GMA, and only two, IL-6 and IL-8, showed a clear decrease throughout the GMA sessions. In view of this outcome, we hypothesize that GMA can help to lower the inflammatory load, thereby enhancing the effect of biologic drugs. To confirm this hypothesis and explore further indications for GMA, we propose the need for research directed toward the characterization of immune cell populations and their specific cytokine production rather than global cytokine assessment. K E Y W O R D Scytokines, granulocyte and monocyte apheresis, ulcerative colitis

show abstract

“…The small differences in gene expression seen in PBMCs between patients with normal colons and those with endoscopic inflammation is not entirely surprising, given the small differences in gene expression, and levels of cytokines, seen peripherally even in patients with severe clinical and endoscopic colitis (23;24). The differential expression of GATA3 in the PBMCs of patients with endoscopic colitis is consistent with its role as a transcriptional regulator of type-2 helper T-cells (Th2), which are important in the pathogenesis of UC (25-27).…”

Section: Discussionmentioning

confidence: 99%

Predictors of Endoscopic Inflammation in Patients With Ulcerative Colitis in Clinical Remission

Rosenberg¹,

Lawlor²,

Zenlea³

et al. 2013

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Objectives Patients with ulcerative colitis (UC) who are in clinical remission may still have underlying endoscopic inflammation, which is associated with inferior clinical outcomes. The goal of this study was to determine the prevalence of, and factors associated with, active endoscopic disease in patients with UC who are in clinical remission. Design Prospective observational study in a single center. Patients with UC in clinical remission (by SCCAI) were enrolled prospectively at time of surveillance colonoscopy. Disease phenotype, endoscopic activity (Mayo sub-score) and histological score (Geboes) were recorded, and blood was drawn for peripheral blood biomarkers. Results 149 patients in clinical remission were prospectively enrolled in this cohort; 81% had been in clinical remission for > 6 months, and 86% were currently prescribed maintenance medications. At endoscopy 45% of patients in clinical remission had any endoscopic inflammation (Mayo endoscopy sub-score >0) and 13% had scores >1. In a multivariate model, variables independently associated with a Mayo endoscopic score >1 were remission for < 6 months (p=.001), WBC (p=0.01) and CRP (p=0.009). A model combining these three variables had a sensitivity of 94% and a specificity of 73% for predicting moderate-severe endoscopic activity in patients in clinical remission (AUC 0.86). In an unselected sub-group of patients who had peripheral blood mononuclear cell mRNA profiling, GATA3 mRNA levels were significantly higher in patients with endoscopic activity. Conclusions Duration of clinical remission, WCC and CRP can predict the probability of on-going endoscopic activity despite clinical remission in patients with UC. These parameters could be used to identify patients who require intensification of treatment to achieve mucosal healing.

show abstract

Role of serum cytokine profile in ulcerative colitis assessment

Abstract: A serum cytokine profile may be an auxiliary tool for the diagnosis and severity assessment of UC. IL-8 seems to be a reliable biomarker, closely related to disease activity.

Cited by 51 publications

References 20 publications

MicroRNA-146aandEts-1gene polymorphisms in ocular Behçet's disease and Vogt–Koyanagi–Harada syndrome

MicroRNA-146aandEts-1gene polymorphisms in ocular Behçet's disease and Vogt–Koyanagi–Harada syndrome

Adsorptive granulocyte/monocyte apheresis use in severe ulcerative colitis and determination of changes in plasma cytokines

Predictors of Endoscopic Inflammation in Patients With Ulcerative Colitis in Clinical Remission

Contact Info

Product

Resources

About